What the trials showed
Not graded yet. Sources are listed below.
What the internet says
“Ipamorelin speeds gut recovery after bowel surgery.”
The gap
Not measured until the claim is graded.
A verdict describes the research, not what’s right for you.
Ipamorelin
Synthetic pentapeptide (ghrelin mimetic / growth hormone secretagogue)
Also known as: Ipamorelin acetate, NNC 26-0161
Classification
Peptide
Regulatory Status
not-established
Sources
4
Review
reviewed · 2026-10-14
Overview
Ipamorelin is a synthetic pentapeptide ghrelin mimetic that stimulates growth hormone release from the anterior pituitary; it was first identified in 1998.
Evidence and limitations
What people claim, and what the evidence says
- NOT YET GRADED
“Ipamorelin speeds gut recovery after bowel surgery.”
Awaiting the two-reviewer evidence council.
- NOT YET GRADED
“Ipamorelin is safe.”
Awaiting the two-reviewer evidence council.
- NOT YET GRADED
“Ipamorelin builds muscle, burns fat and slows aging.”
Awaiting the two-reviewer evidence council.
Known
- FDA lists ipamorelin acetate among bulk drug substances that may present significant safety risks for compounding, citing risk of immunogenicity for certain routes of administration due to potential aggregation or peptide-related impurities; the page additionally notes serious adverse events including death associated with intravenous administration.
- In its Pharmacy Compounding Advisory Committee briefing, FDA concluded the evaluation criteria weigh against placing ipamorelin (free base) and ipamorelin acetate on the 503A Bulks List, citing immunogenicity potential from impurities and peptide-related aggregates, possible stimulation of reward processing with potential for reinforcing and addictive behaviors, and possible negative effects on reproductive health and pregnancy outcomes.
- Ipamorelin is a synthetic pentapeptide ghrelin mimetic that stimulates growth hormone release from the anterior pituitary; it was first identified in 1998.
Unknown
- Human efficacy for anti-aging, body-composition, or chronic subcutaneous self-administration is unestablished.
- No approved ipamorelin product exists, and the published controlled human evidence does not address the anti-aging, body-composition, recovery, or growth-hormone-optimization uses for which ipamorelin (often combined with CJC-1295) is commonly marketed online; human efficacy and safety for those uses and for chronic subcutaneous self-administration are unestablished.
- Community-reported doses: n/a (no citable source).
Studied uses
- studied as a ghrelin-mimetic GH secretagogue; commonly discussed for recovery/body-composition contexts without approved indicationnot indicatedPeople look up ipamorelin for growth-hormone secretagogue effects; the principal published human RCT (postoperative ileus) did not meet its primary endpoint, and FDA has raised compounding safety concerns including immunogenicity.
Dangers and side effects
Contraindications
- No approved ipamorelin product; FDA has flagged bulk ipamorelin acetate among substances that may present significant compounding safety risks. (high)Confirm full labeled contraindications or regulator warnings before any clinical use.
Warnings
- Immunogenicity and impurity/aggregation concerns; serious adverse events including death have been associated with intravenous administration in FDA safety communications. Gray-market injection risk applies. (high)Educational reference only; not a recommendation.
Common: not fully characterized for chronic subcutaneous wellness use
- Serious
- immunogenicity
- serious events with IV administration (FDA)
- unknown reproductive effects (FDA PCAC briefing concerns)
Study details: trial conditions, not guidance
These are the conditions researchers used in a controlled trial with medical supervision. They aren't instructions.
Doses found
Doses as found in each source, with its grade. What was found, not a direction.
Studies, trials and professional sources
0.03 mg/kg · twice daily · intravenous · up to 7 days
114 adults after bowel resection
no significant difference vs placebo
Grade: UnsupportedIpamorelin for postoperative ileus (Int J Colorectal Dis 2014) (opens in a new tab)
Reddit, Facebook, Instagram, forums and blogs
n/a
Claims and grades
- EstablishedFDA lists ipamorelin acetate among bulk drug substances that may present significant safety risks for compounding, citing risk of immunogenicity for certain routes of administration due to potential aggregation or peptide-related impurities; the page additionally notes serious adverse events including death associated with intravenous administration.
- EstablishedIn its Pharmacy Compounding Advisory Committee briefing, FDA concluded the evaluation criteria weigh against placing ipamorelin (free base) and ipamorelin acetate on the 503A Bulks List, citing immunogenicity potential from impurities and peptide-related aggregates, possible stimulation of reward processing with potential for reinforcing and addictive behaviors, and possible negative effects on reproductive health and pregnancy outcomes.
- EstablishedIpamorelin is a synthetic pentapeptide ghrelin mimetic that stimulates growth hormone release from the anterior pituitary; it was first identified in 1998.
- ContradictedIn the principal published human efficacy trial - a multicenter, double-blind, placebo-controlled phase 2 study in 117 bowel-resection patients - intravenous ipamorelin [dose: see Study details]/kg twice daily did not significantly accelerate recovery from postoperative ileus versus placebo (median time to first tolerated meal 25.3 vs 32.6 hours, p = 0.15); the regimen was reported as well tolerated in that setting, and FDA's briefing notes development for this indication was subsequently discontinued.
- Hype Exceeds EvidenceNo approved ipamorelin product exists, and the published controlled human evidence does not address the anti-aging, body-composition, recovery, or growth-hormone-optimization uses for which ipamorelin (often combined with CJC-1295) is commonly marketed online; human efficacy and safety for those uses and for chronic subcutaneous self-administration are unestablished.
Contested
- Online stacks with CJC-1295 are heavily marketed despite thin controlled human evidence for those uses.
Sources (4)
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (opens in a new tab) · U.S. Food and Drug Administration · regulator
- FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting (ipamorelin evaluation) (opens in a new tab) · U.S. Food and Drug Administration · regulator
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (opens in a new tab) · International Journal of Colorectal Disease (Beck DE, Sweeney WB, McCarter MD, et al., 2014) · other · 2014-01-01
- PubChem Compound Summary: Ipamorelin (CID 9831659) (opens in a new tab) · National Center for Biotechnology Information / PubChem · other
Interactions & cautions
Drug interactions
other GH secretagogues or recombinant GH — Unpredictable IGF-1 elevation (review)
These are observational flags for review, not individualized instructions.
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
not fully characterized for chronic subcutaneous wellness use · immunogenicity · serious events with IV administration (FDA) · unknown reproductive effects (FDA PCAC briefing concerns)
Effects measured:
studied as a ghrelin-mimetic GH secretagogue; commonly discussed for recovery/body-composition contexts without approved indication
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw